Literature DB >> 16832074

Dissociating apathy and depression in Parkinson disease.

L Kirsch-Darrow1, H H Fernandez, H F Fernandez, M Marsiske, M S Okun, D Bowers.   

Abstract

OBJECTIVE: To examine the hypothesis that apathy is a core feature of Parkinson disease (PD) and that apathy can be dissociated from depression.
METHODS: Eighty patients with PD and 20 patients with dystonia completed depression and apathy measures including the Marin Apathy Evaluation Scale (AES), Beck Depression Inventory (BDI), and Centers for Epidemiologic Studies-Depression Scale (CES-D).
RESULTS: There was a significantly higher severity and frequency of apathy in PD (frequency = 51%, 41/80) than in dystonia (frequency = 20%, 4/20). Apathy in the absence of depression was frequent in PD and did not occur in dystonia (PD = 28.8%, dystonia = 0%).
CONCLUSIONS: Patients with Parkinson disease (PD) experienced significantly higher frequency and severity of apathy when compared with patients with dystonia. Apathy may be a "core" feature of PD and occurs in the absence of depression.

Entities:  

Mesh:

Year:  2006        PMID: 16832074      PMCID: PMC2911155          DOI: 10.1212/01.wnl.0000230572.07791.22

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  Negative symptoms: the 'pathology' of motivation and goal-directed behaviour.

Authors:  R G Brown; G Pluck
Journal:  Trends Neurosci       Date:  2000-09       Impact factor: 13.837

Review 2.  Apathy: why care?

Authors:  Robert van Reekum; Donald T Stuss; Laurie Ostrander
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2005       Impact factor: 2.198

3.  The Center for Epidemiological Studies-Depression (CES-D) Scale: assessment of depression in the medically ill elderly.

Authors:  R L Schein; H G Koenig
Journal:  Int J Geriatr Psychiatry       Date:  1997-04       Impact factor: 3.485

4.  Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease.

Authors:  D Aarsland; I Litvan; J P Larsen
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2001       Impact factor: 2.198

5.  Poststroke apathy and regional cerebral blood flow.

Authors:  K Okada; S Kobayashi; S Yamagata; K Takahashi; S Yamaguchi
Journal:  Stroke       Date:  1997-12       Impact factor: 7.914

6.  Reliability, validity, and clinical correlates of apathy in Parkinson's disease.

Authors:  S E Starkstein; H S Mayberg; T J Preziosi; P Andrezejewski; R Leiguarda; R G Robinson
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1992       Impact factor: 2.198

7.  Range of neuropsychiatric disturbances in patients with Parkinson's disease.

Authors:  D Aarsland; J P Larsen; N G Lim; C Janvin; K Karlsen; E Tandberg; J L Cummings
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-10       Impact factor: 10.154

8.  Apathy is not depression.

Authors:  M L Levy; J L Cummings; L A Fairbanks; D Masterman; B L Miller; A H Craig; J S Paulsen; I Litvan
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1998       Impact factor: 2.198

9.  Apathy following cerebrovascular lesions.

Authors:  S E Starkstein; J P Fedoroff; T R Price; R Leiguarda; R G Robinson
Journal:  Stroke       Date:  1993-11       Impact factor: 7.914

Review 10.  Frontal-subcortical circuits and human behavior.

Authors:  J L Cummings
Journal:  Arch Neurol       Date:  1993-08
View more
  74 in total

1.  Latent growth-curve analysis reveals that worsening Parkinson's disease quality of life is driven by depression.

Authors:  Jacob D Jones; Michael Marsiske; Michael S Okun; Dawn Bowers
Journal:  Neuropsychology       Date:  2014-11-03       Impact factor: 3.295

2.  Mood and motor trajectories in Parkinson's disease: multivariate latent growth curve modeling.

Authors:  Laura B Zahodne; Michael Marsiske; Michael S Okun; Ramon L Rodriguez; Irene Malaty; Dawn Bowers
Journal:  Neuropsychology       Date:  2011-12-05       Impact factor: 3.295

3.  Apathy and depression: separate factors in Parkinson's disease.

Authors:  Lindsey Kirsch-Darrow; Michael Marsiske; Michael S Okun; Russell Bauer; Dawn Bowers
Journal:  J Int Neuropsychol Soc       Date:  2011-11       Impact factor: 2.892

Review 4.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

Review 5.  Are the available apathy measures reliable and valid? A review of the psychometric evidence.

Authors:  Diana E Clarke; Jean Y Ko; Emily A Kuhl; Robert van Reekum; Rocio Salvador; Robert S Marin
Journal:  J Psychosom Res       Date:  2010-03-31       Impact factor: 3.006

6.  Emotion and ocular responses in Parkinson's disease.

Authors:  J Dietz; M M Bradley; M S Okun; D Bowers
Journal:  Neuropsychologia       Date:  2011-08-04       Impact factor: 3.139

7.  Depressive traits in essential tremor: impact on disability, quality of life, and medication adherence.

Authors:  E D Louis; E D Huey; M Gerbin; A S Viner
Journal:  Eur J Neurol       Date:  2012-05-29       Impact factor: 6.089

8.  Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's disease?

Authors:  Laura B Zahodne; Oscar Bernal-Pacheco; Dawn Bowers; Herbert Ward; Genko Oyama; Natlada Limotai; Frances Velez-Lago; Ramon L Rodriguez; Irene Malaty; Nikolaus R McFarland; Michael S Okun
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2012       Impact factor: 2.198

9.  The late positive potential, emotion and apathy in Parkinson's disease.

Authors:  J Dietz; M M Bradley; J Jones; M S Okun; W M Perlstein; D Bowers
Journal:  Neuropsychologia       Date:  2013-01-12       Impact factor: 3.139

10.  Toys and gadgets: construct validity of apathy in Parkinson's disease.

Authors:  Beata Ferencz; Bart Scholtissen; Milana Bogorodskaya; Michael S Okun; Dawn Bowers
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2012       Impact factor: 2.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.